View More View Less
  • 1 Pécsi Tudományegyetem, Általános Orvostudományi Kar Orvosi Biológiai Intézet Pécs Szigeti u. 12. 7624
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Az emberi megbetegedések kezelésére kifejlesztett újszerű gyógymódok gyakorlati bevezetése nem egyszerű feladat. Egyrészt a modern terápiák számos kritériumnak kell hogy megfeleljenek, másrészt gyakorta szélsőséges várakozásokat kell kielégíteniük; a betegek és terapeuták euforikus hangulatát a kezdeti nehézségeket követően könnyen válthatja az új gyógymód iránti mély pesszimizmus. Ez alól a daganatok vírusok segítségével történő gyógyításának ötlete sem kivétel. Az első próbálkozásokat követően tapasztalt nehézségek, komplikációk és a tökéletes gyógyhatás elmaradása rövid időn belül az onkolitikus vírusterápia elvetéséhez vezetett. Az elmúlt évtizedek molekuláris és sejtbiológiai felfedezéseinek köszönhetően az onkolitikus vírusterápia újra reflektorfénybe került, melyet a világ több pontján jelenleg is zajló klinikai próbák követtek. A jelen összefoglaló célja az onkolitikus vírusterápia jelenlegi helyzetének bemutatása, illetve az eddigi eredmények összefoglalása.

  • Dock, G.: Rabies virus vaccination in a patient with cervical carcinoma. Am. J. Med. Sci., 1904, 127 , 563.

    Dock G. , 'Rabies virus vaccination in a patient with cervical carcinoma ' (1904 ) 127 Am. J. Med. Sci. : 563 -.

    • Search Google Scholar
  • Sunamura, M., Hamada, H., Motoi, F. és mtsai: Oncolytic virotherapy as a novel strategy for pancreatic cancer. Pancreas, 2004, 28 , 326–329.

    Motoi F. , 'Oncolytic virotherapy as a novel strategy for pancreatic cancer ' (2004 ) 28 Pancreas : 326 -329.

    • Search Google Scholar
  • Heideman, D. A.: Gene therapy and virotherapy of gastric cancer: preclinical results and clinical developments. Dig. Dis., 2004, 22 , 374–379.

    Heideman D. A. , 'Gene therapy and virotherapy of gastric cancer: preclinical results and clinical developments ' (2004 ) 22 Dig. Dis. : 374 -379.

    • Search Google Scholar
  • Kirn, D.: Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin. Biol. Ther., 2001, 1 , 525–538.

    Kirn D. , 'Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials ' (2001 ) 1 Expert Opin. Biol. Ther. : 525 -538.

    • Search Google Scholar
  • Barzon, L., Zanusso, M., Colombo, F. és mtsai: Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas. Cancer Gene Ther., 2006, 13 , 539–554.

    Colombo F. , 'Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas ' (2006 ) 13 Cancer Gene Ther. : 539 -554.

    • Search Google Scholar
  • Mullen, J. T., Tanabe, K. K.: Viral oncolysis. Oncologist, 2002, 7 , 106–119.

    Tanabe K. K. , 'Viral oncolysis ' (2002 ) 7 Oncologist : 106 -119.

  • Schirrmacher, V.: Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol. Immunother., 2005, 54 , 587–598.

    Schirrmacher V. , 'Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory ' (2005 ) 54 Cancer Immunol. Immunother. : 587 -598.

    • Search Google Scholar
  • Huebner, R. J., Rowe, W. P., Schatten, W. E. és mtsai: Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer, 1956, 9 , 1211–1218.

    Schatten W. E. , 'Studies on the use of viruses in the treatment of carcinoma of the cervix ' (1956 ) 9 Cancer : 1211 -1218.

    • Search Google Scholar
  • Mineta, T., Rabkin, S. D., Yazaki, T. és mtsai: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., 1995, 1 , 938–943.

    Yazaki T. , 'Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas ' (1995 ) 1 Nat. Med. : 938 -943.

    • Search Google Scholar
  • Miyatake, S., Iyer, A., Martuza, R. L. és mtsai: Transcriptional targeting of herpes simplex virus for cell-specific replication. J. Virol., 1997, 71 , 5124–5132.

    Martuza R. L. , 'Transcriptional targeting of herpes simplex virus for cell-specific replication ' (1997 ) 71 J. Virol. : 5124 -5132.

    • Search Google Scholar
  • Markert, J. M., Medlock, M. D. Rabkin, S. D. és mtsai: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther., 2000, 7 , 867–874.

    Rabkin S. D. , 'Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial ' (2000 ) 7 Gene Ther. : 867 -874.

    • Search Google Scholar
  • Harada, J. N. Berk, A. J.: p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol., 1999, 73 , 5333–5344.

    Berk A. J. , 'p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication ' (1999 ) 73 J. Virol. : 5333 -5344.

    • Search Google Scholar
  • Dummer, R., Bergh, J. Karlsson, Y. és mtsai: Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors. Cancer Gene Ther., 2000, 7 , 1069–1076.

    Karlsson Y. , 'Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors ' (2000 ) 7 Cancer Gene Ther. : 1069 -1076.

    • Search Google Scholar
  • Yin, S., Hung, M. C., Goodrich, D. W.: Adenovirus-mediated N5 gene transfer inhibits tumor cell proliferation by induction of apoptosis. Cancer Gene Ther., 2000, 7 , 985–990.

    Goodrich D. W. , 'Adenovirus-mediated N5 gene transfer inhibits tumor cell proliferation by induction of apoptosis ' (2000 ) 7 Cancer Gene Ther. : 985 -990.

    • Search Google Scholar
  • Rodriguez, R., Schuur, E. R. Lim, H. Y. és mtsai: Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res., 1997, 57 , 2559–2563.

    Lim H. Y. , 'Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells ' (1997 ) 57 Cancer Res. : 2559 -2563.

    • Search Google Scholar
  • Hallenbeck, P. L., Chang, Y. N., Hay, C. és mtsai: A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther., 1999, 10 , 1721–1733.

    Hay C. , 'A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma ' (1999 ) 10 Hum. Gene Ther. : 1721 -1733.

    • Search Google Scholar
  • Kurihara, T., Brough, D. E., Kovesdi, I. és mtsai: Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest., 2000, 106 , 763–771.

    Kovesdi I. , 'Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen ' (2000 ) 106 J. Clin. Invest. : 763 -771.

    • Search Google Scholar
  • Li, Y., Chen, Y., Dilley, J. és mtsai: Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy. Mol. Cancer Ther., 2003, 2 , 1003–1009.

    Dilley J. , 'Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy ' (2003 ) 2 Mol. Cancer Ther. : 1003 -1009.

    • Search Google Scholar
  • Yamamoto, M., Davydova, J., Wang, M. és mtsai: Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology, 2003, 125 , 1203–1218.

    Wang M. , 'Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer ' (2003 ) 125 Gastroenterology : 1203 -1218.

    • Search Google Scholar
  • Vasey, P. A., Shulman, L. N. Campos, S. és mtsai: Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol., 2002, 20 , 1562–1569.

    Campos S. , 'Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer ' (2002 ) 20 J. Clin. Oncol. : 1562 -1569.

    • Search Google Scholar
  • Reid, T.: Hepatic artery infusion of ONYX-015 a replication-selective adenovirus, in combination with 5-FU/leucovorin for gastrointestinal carcinoma metastatic to the liver: A Phase I/II clinical trial. PASCO, 2000, 953.

  • Reid, T., Galanis, E., Abbruzzese, J. és mtsai: Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res., 2002, 62 , 6070–6079.

    Abbruzzese J. , 'Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints ' (2002 ) 62 Cancer Res. : 6070 -6079.

    • Search Google Scholar
  • Thorne, S. H., Hermiston, T. Kirn, D.: Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects. Semin. Oncol., 2005, 32 , 537–548.

    Kirn D. , 'Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects ' (2005 ) 32 Semin. Oncol. : 537 -548.

    • Search Google Scholar
  • Puhlmann, M., Brown, C. K. Gnant, M. és mtsai: Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther., 2000, 7 , 66–73.

    Gnant M. , 'Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant ' (2000 ) 7 Cancer Gene Ther. : 66 -73.

    • Search Google Scholar
  • Qin, H. Chatterjee, S. K.: Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. Hum. Gene Ther., 1996, 7 , 1853–1860.

    Chatterjee S. K. , 'Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF ' (1996 ) 7 Hum. Gene Ther. : 1853 -1860.

    • Search Google Scholar
  • Mastrangelo, M. J., Maguire, H. C. Jr., Eisenlohr, L. C. és mtsai: Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther., 1999, 6 , 409–422.

    Eisenlohr L. C. , 'Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma ' (1999 ) 6 Cancer Gene Ther. : 409 -422.

    • Search Google Scholar
  • Mukherjee, S., Haenel, T. Himbeck, R. és mtsai: Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene, Ther., 2000, 7 , 663–670.

    Himbeck R. , 'Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation ' (2000 ) 7 Cancer Gene, Ther. : 663 -670.

    • Search Google Scholar
  • McCart, J. A., Puhlmann, M. Lee, J. és mtsai: Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene, Ther., 2000, 7 , 1217–1223.

    Lee J. , 'Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression ' (2000 ) 7 Gene, Ther. : 1217 -1223.

    • Search Google Scholar
  • Gromeier, M., Lachmann, S. Rosenfeld, M. R. és mtsai: Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl. Acad. Sci. USA, 2000, 97 , 6803–6808.

    Rosenfeld M. R. , 'Intergeneric poliovirus recombinants for the treatment of malignant glioma ' (2000 ) 97 Proc. Natl. Acad. Sci. USA : 6803 -6808.

    • Search Google Scholar
  • Hashiro, G., Loh, P. C. Yau, J. T.: The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch. Virol., 1977, 54 , 307–315.

    Yau J. T. , 'The preferential cytotoxicity of reovirus for certain transformed cell lines ' (1977 ) 54 Arch. Virol. : 307 -315.

    • Search Google Scholar
  • Strong, J. E., Tang, D. Lee, P. W.: Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency. Virology, 1993, 197 , 405–411.

    Lee P. W. , 'Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency ' (1993 ) 197 Virology : 405 -411.

    • Search Google Scholar
  • Strong, J. E., Coffey, M. C. Tang, D. és mtsai: The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. Embo. J., 1998, 17 , 3351–3362.

    Tang D. , 'The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus ' (1998 ) 17 Embo. J. : 3351 -3362.

    • Search Google Scholar
  • Fauquet, C., Mayo, M. A. Maniloff, J. és mtsai: Virus Taxonomy, VIIIth Report of the International Committee on Taxonomy of Viruses. Academic Press, 2005, 1–1162.

  • Lorence, R. M., Rood P. A. Kelley, K. W.: Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity. J. Natl. Cancer Inst., 1988, 80 , 1305–1312.

    Kelley K. W. , 'Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity ' (1988 ) 80 J. Natl. Cancer Inst. : 1305 -1312.

    • Search Google Scholar
  • Batliwalla, F. M., Bateman B. A., Serrano, D. és mtsai: A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol. Med., 1998, 4 , 783–794.

    Serrano D. , 'A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire ' (1998 ) 4 Mol. Med. : 783 -794.

    • Search Google Scholar
  • Csatary L. K., Gosztonyi G., Szeberenyi J. és mtsai: MTH-68/H oncolytic viral treatment in human high-grade gliomas. J. Neurooncol., 2004, 67 , 83–93.

    Szeberenyi J. , 'MTH-68/H oncolytic viral treatment in human high-grade gliomas ' (2004 ) 67 J. Neurooncol. : 83 -93.

    • Search Google Scholar
  • Ries, S. J. Brandts, C. H.: Oncolytic viruses for the treatment of cancer: current strategies and clinical trials. Drug Discov. Today, 2004, 9 , 759–768.

    Brandts C. H. , 'Oncolytic viruses for the treatment of cancer: current strategies and clinical trials ' (2004 ) 9 Drug Discov. Today : 759 -768.

    • Search Google Scholar
  • Czegledi A., Wehmann E., Lomniczi B.: On the origins and relationships of Newcastle disease virus vaccine strains Hertfordshire and Mukteswar, and virulent strain Herts’33. Avian Pathol., 2003, 32 , 271–276.

    Lomniczi B. , 'On the origins and relationships of Newcastle disease virus vaccine strains Hertfordshire and Mukteswar, and virulent strain Herts’33 ' (2003 ) 32 Avian Pathol. : 271 -276.

    • Search Google Scholar
  • Bischoff, J. R., Kirn, D. H. Williams, A. és mtsai: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science, 1996, 274 , 373–376.

    Williams A. , 'An adenovirus mutant that replicates selectively in p53-deficient human tumor cells ' (1996 ) 274 Science : 373 -376.

    • Search Google Scholar
  • Khuri, F. R., Nemunaitis, J. Ganly, I. és mtsai: a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med., 2000, 6 , 879–885.

    Ganly I. , 'a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer ' (2000 ) 6 Nat. Med. : 879 -885.

    • Search Google Scholar
  • Ganly, I., Kirn, D., Eckhardt, G. és mtsai: A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res., 2000, 6 , 798–806.

    Eckhardt G. , 'A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer ' (2000 ) 6 Clin. Cancer Res. : 798 -806.

    • Search Google Scholar
  • Heise, C., Ganly, I. Kim, Y. T. és mtsai: Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene Ther., 2000, 7 , 1925–1929.

    Kim Y. T. , 'Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status ' (2000 ) 7 Gene Ther. : 1925 -1929.

    • Search Google Scholar
  • DeWeese, T. L., van der Poel, H., Li, S. és mtsai: A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res., 2001, 61 , 7464–7472.

    Li S. , 'A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy ' (2001 ) 61 Cancer Res. : 7464 -7472.

    • Search Google Scholar
  • Chen, Y., DeWeese, T. Dilley, J. és mtsai: CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res., 2001, 61 , 5453–5460.

    Dilley J. , 'CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity ' (2001 ) 61 Cancer Res. : 5453 -5460.

    • Search Google Scholar
  • Yu, D. C., Chen, Y. Dilley, J. és mtsai: Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res., 2001, 61 , 517–525.

    Dilley J. , 'Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel ' (2001 ) 61 Cancer Res. : 517 -525.

    • Search Google Scholar
  • Kim, S. H., Wong, R. J. Kooby, D. A. és mtsai: Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck. Eur. J. Cancer, 2005, 41 , 313–322.

    Kooby D. A. , 'Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck ' (2005 ) 41 Eur. J. Cancer : 313 -322.

    • Search Google Scholar
  • Nakano, K., Todo, T., Zhao, G. és mtsai: Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. J. Gene Med., 2005, 7 , 638–648.

    Zhao G. , 'Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models ' (2005 ) 7 J. Gene Med. : 638 -648.

    • Search Google Scholar
  • Cinatl, J., Jr., Cinatl, J. Michaelis, M. és mtsai: Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res., 2003, 63 , 1508–1514.

    Michaelis M. , 'Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma ' (2003 ) 63 Cancer Res. : 1508 -1514.

    • Search Google Scholar
  • Bennett, J. J., Delman, K. A. Burt, B. M. és mtsai: Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther., 2002, 9 , 935–945.

    Burt B. M. , 'Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer ' (2002 ) 9 Cancer Gene Ther. : 935 -945.

    • Search Google Scholar
  • Oyama, M., Ohigashi, T., Hoshi, M. és mtsai: Treatment of human renal cell carcinoma by a conditionally replicating herpes vector G207. J. Urol., 2001, 165 , 1274–1278.

    Hoshi M. , 'Treatment of human renal cell carcinoma by a conditionally replicating herpes vector G207 ' (2001 ) 165 J. Urol. : 1274 -1278.

    • Search Google Scholar
  • Varghese, S., Newsome, J. T. Rabkin, S. D. és mtsai: Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum. Gene Ther., 2001, 12 , 999–1010.

    Rabkin S. D. , 'Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates ' (2001 ) 12 Hum. Gene Ther. : 999 -1010.

    • Search Google Scholar
  • Wallack, M. K., Sivanandham, M. Balch, C. M. és mtsai: Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J. Am. Coll. Surg., 1998, 187 , 69–77, discussion 77–79.

    Balch C. M. , 'Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial ' (1998 ) 187 J. Am. Coll. Surg. : 69 -77.

    • Search Google Scholar
  • Chatterjee, S. K., Qin, H. Manna, S. és mtsai: Recombinant vaccinia virus expressing cytokine GM-CSF as tumor vaccine. Anticancer Res., 1999, 19 , 2869–2873.

    Manna S. , 'Recombinant vaccinia virus expressing cytokine GM-CSF as tumor vaccine ' (1999 ) 19 Anticancer Res. : 2869 -2873.

    • Search Google Scholar